Identification of populations likely to benefit from pharmacogenomic testing
Conclusion
We demonstrate a significant number of patients in each group may have benefit, but targeting certain ones for pre-emptive testing may result in the initial highest yield for a health system.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
More News: Celexa | Citalopram | Clopidogrel | Genetics | Lexapro | Pediatrics | Plavix | Psychiatry | Simvastatin | Statin Therapy | Toprol | Tramadol | Zocor | Zofran